Capcom’s Monster Hunter Bridge to be Exhibited in the Osaka Healthcare Pavilion at Expo 2025, Osaka, Kansai, Japan!
29.8.2024 15:00:00 EEST | Business Wire | Press release
Capcom Co., Ltd. (TOKYO:9697) today announced that the company will sponsor the Osaka Healthcare Pavilion, which is being exhibited by the Expo 2025, Osaka Pavilion Promotion Committee at Expo 2025, Osaka, Kansai, Japan (Expo 2025, below). Further, the company announced that it will exhibit an interactive experience dubbed Monster Hunter Bridge at the Pavilion in the XD Hall, where visitors can experience the future of entertainment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240829488620/en/
Monster Hunter Bridge key art (Graphic: Business Wire)
The theme of the upcoming Expo 2025 is “Designing Future Society for Our Lives.” Inspired by the “REBORN” theme of the Osaka Healthcare Pavilion, Capcom decided to exhibit an interactive attraction that incorporates the concept of nature, living things, and the wonder of life, which are important themes in the Monster Hunter series.
Exhibit Details
Monster Hunter Bridge is a wholly-unique attraction that Capcom created exclusively for Expo 2025. Visitors to the hall will don specialized AR devices and be able to enjoy this interactive attraction that weaves together a 360-degree theater, immersive audio, and vibrating floor. Capcom is developing Monster Hunter Bridge with the aim of blending dreams with reality to provide an immersive experience like never before. The company hopes that visitors look forward to this one-of-a-kind Monster Hunter attraction that will bring them up close with Felyne as well as incredible monster encounters, and can only be experienced at Expo 2025.
Facilities Details
The attraction will be housed in a cylinder-shaped theater within the XD Hall that will measure approximately 12 meters in diameter and 5 meters in height and will be created as part of the Osaka Healthcare Pavilion. Capcom will exhibit Monster Hunter Bridge there by creating a space inside the XD Hall that projects the world of Monster Hunter in 360 degrees, utilizing transparent LED displays on the internal walls and ceiling and projectors on the floor. The company developed new specialized AR devices for visitors that feature 105 degrees of visibility in order to create Expo 2025’s most engaging experience. In addition, the company will enhance the immersion of the space by outfitting it with a multitude of speakers set behind the transparent LED displays, wrapping visitors in 360 degrees of sound while vibrations from the floor are synchronized with the on-screen action.
The company is creating these facilities with the cooperation of partner companies exclusively for Monster Hunter Bridge.
Promotional Ticket Campaign
With the desire to contribute to the development and promotion of Expo 2025, which is being held where Capcom was founded, the company will carry out an Expo 2025 “super-advanced one-day pass” double ticket promotional campaign in which it will give away a total of 80,890 tickets to Expo 2025. The promotion is available to everyone who registers for Capcom ID, a unified account with which users can conveniently manage various Capcom games and web services. The company encourages people to refer to the promotional ticket campaign website for more details.
*Only residents of Japan are eligible to participate in the round one entry period. Please refer to the promotional ticket campaign website regarding eligibility for future campaign entry periods.
Capcom is currently developing Monster Hunter Bridge with the aim of providing a special entertainment experience where dreams and reality become one. The company hopes to create the absolute best content at the event and bring success to the Expo 2025, Osaka Pavilion Promotion Committee.
ABOUT the Monster Hunter series:
The Monster Hunter series consists of hunting action games that pit players against giant monsters in beautiful natural environments. After the series created a social phenomenon through play on handheld consoles and solidified its standing as one of Japan’s most beloved game series, it went on to global-brand status with the release of Monster Hunter: World in 2018. With cumulative sales of the series now exceeding 100 million units, Monster Hunter has grown into a global phenomenon.
[Exhibit Details]
1. Name | Monster Hunter Bridge |
2. Location | XD Hall, Osaka Healthcare Pavilion, Expo 2025, Osaka, Kansai |
3. Term | April 13, 2025 - October 13, 2025 |
4. Admission | Free* |
5. Official Website | |
6. Ticket Promotion Website | |
*Entry to this attraction will be by reservation only. Details will be provided at a later date. | |
*A separate ticket must be purchased to enter Expo 2025, Osaka, Kansai. | |
ABOUT CAPCOM
Capcom is a leading worldwide developer, publisher and distributor of interactive entertainment for game consoles, PCs, handheld and wireless devices. Founded in 1983, the company has created hundreds of games, including groundbreaking franchises Resident Evil™, Monster Hunter™, Street Fighter™, Mega Man™, Devil May Cry™ and Ace Attorney™. Capcom maintains operations in the U.S., U.K., Germany, France, Hong Kong, Taiwan, Singapore and Tokyo, with corporate headquarters located in Osaka, Japan. More information about Capcom can be found at https://www.capcom.co.jp/ir/english/
View source version on businesswire.com: https://www.businesswire.com/news/home/20240829488620/en/
Contacts
Capcom Public Relations & Investor Relations Section
Daniel Levine
+81-6-6920-3623
daniel-levine@capcom.com
Yoshiko Ikeda
+81-6-6920-3623
yoshiko-ikeda@capcom.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 16:00:00 EEST | Press release
Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's core mission has always been to increase access to life-saving treatments. It’s about getting the right information to the right care tea
Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 16:00:00 EEST | Press release
Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become operational infrastructure without corresponding security maturity. The report also reveals that AI environments are rapidly becoming more interconnected and business critical. Among organizations adopting AI, 64% now run vector databases, 55
Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 16:00:00 EEST | Press release
As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructure to monitor airspace activity. The new 86,350-square-foot facility is a major step in readying supply for multiple, large, global markets. The
SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 15:51:00 EEST | Press release
The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus ® (ocrelizumab) for Multiple Sclerosis9.7.2026 15:45:00 EEST | Press release
Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260709701277/en/ “This agreement reflects our focus on pushing high-quality biologics to the finish line efficiently and at scale,” said Anjan Selz, Chief Executive Officer of Polpharma Biologics International AG. “Teva brings reach, discipline and real commercial strength to our strategic collaboration. Combining its global footprint with our technical and develo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom